PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry

New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to MarketBOSTON, November 15, 2017 — PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially viable, reimbursable... Source: RealWire

Read More